Previous 10 | Next 10 |
Data show d ose - dependent suppression of immun e- suppressive agents GEN-1 stimulate s the immune system through the production of CD4 and CD8 cells C hemotherapy R esponse Score tripled in the two highe...
Celsion ([[CLSN]] -3.8%) announces that following a pre-planned interim safety review of 55 as treated patients in Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data Safety Monitoring Board ((DSMB)) has unanimously recommended that the OVATION 2 Study co...
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene- M ediated Immunotherapy is Safe and Demonstrates an Acceptable R isk/ B enefit W hen Administered O ver a Six-Month ...
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in biotech penny stocks is somewhat like pursuing a career in TV acting: It’s not easy to succeed, but if you do so, your rewards can be truly fantastic. Further, just as many unsuccessful actors make lit...
LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanD...
Celsion GmbH will manage current and future cancer studies with Thermo D ox ® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEW...
Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) ...
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-ba...
49% of S hares V oted, Q uorum N ot E stablished To Hold Annual Meeting Polls Remain Open Stockholders H olding U nvoted Proxies A re S trongly E ncouraged to V ote T he...
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...